Forgot password

The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.


NNECOS Lunchtime Best Oncology Practice Series


New Job Posted - NNECOS Classifieds

  • UVM Cancer Center - PhD Cancer Research, Scientist - Assistant Professor - Education Scholar Pathway

  • UVM Medical Center - Clinical Program Coordinator - Hematology 

nnecos sponsored grief retreat a success!

Learn more about this inspiring event, funded by a NNECOS Educational Program Grant! 

eDUCATIONAL PROGRAM GRANTS

Learn more about our unique funding program! 

Get Involved with a NNECOS Task Force


State Advocacy

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



ASCO Twitter Feeds

SOCIAL MEDIA

 

Upcoming events

31 Dec 2022 • Maine, New Hampshire, Vermont
13 Apr 2023 12:15 PM •
11 May 2023 12:15 PM •
08 Jun 2023 12:15 PM •
13 Jul 2023 12:15 PM •
10 Aug 2023 12:15 PM •
14 Sep 2023 12:15 PM •
12 Oct 2023 12:15 PM •
09 Nov 2023 12:15 PM •
14 Dec 2023 12:15 PM •

NNECOS News

NNECOS News

Thank You Corporate Members!


CANCER COMMUNITY SUPPORT


Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • March 22 - FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma
  • March 16 - FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
  • March 3 - FDA expands early breast cancer indication for abemaciclib with endocrine therapy
  • February 9 - FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
  • February 3 - FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
  • January 27 - FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
  • January 27 - FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma
  • January 26 - FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
Package/Label Updates
    Code Updates

    Other Updates


    Group Practice Members

    Because your entire team benefits
    from being a part of NNECOS!
    Special thanks to our 2023 Diamond & Platinum Corporate Members!

       
       

     

    		  
      

    Platinum Members



    		 
    		  




    		 
    		    
    		  
             

    View the complete list of corporate members.

    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software